BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 33939583)

  • 1. A retrospective study assessing the accuracy of [18F]-fluorocholine PET/CT for primary staging of lymph node metastases in intermediate and high-risk prostate cancer patients undergoing robotic-assisted laparoscopic prostatectomy with extended lymph node dissection.
    Puterman C; Bjöersdorff M; Amidi J; Anand A; Soller W; Jiborn T; Kjölhede H; Trägårdh E; Bjartell A
    Scand J Urol; 2021 Aug; 55(4):293-297. PubMed ID: 33939583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.
    Poulsen MH; Bouchelouche K; Høilund-Carlsen PF; Petersen H; Gerke O; Steffansen SI; Marcussen N; Svolgaard N; Vach W; Geertsen U; Walter S
    BJU Int; 2012 Dec; 110(11):1666-71. PubMed ID: 22520686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard.
    Stabile A; Pellegrino A; Mazzone E; Cannoletta D; de Angelis M; Barletta F; Scuderi S; Cucchiara V; Gandaglia G; Raggi D; Necchi A; Karakiewicz P; Montorsi F; Briganti A
    Eur Urol Oncol; 2022 Feb; 5(1):1-17. PubMed ID: 34538770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymph node staging with 68Ga-PSMA PET in patients with intermediate and high-risk prostate cancer suitable for radical prostatectomy managed in a prostate cancer unit.
    Maestroni UV; Campobasso D; Guarino G; Acampora A; Scarlattei M; Ziglioli F; Dinale F; Baldari G; Migliari S; Gasparro D; Ferretti S; Silini EM; Ruffini L
    Chin Clin Oncol; 2023 Jun; 12(3):22. PubMed ID: 37417288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How accurate is
    Erdem S; Simsek DH; Degirmenci E; Aydin R; Bagbudar S; Ozluk Y; Sanli Y; Sanli O; Ozcan F
    Urol Oncol; 2022 Jan; 40(1):6.e1-6.e9. PubMed ID: 34400066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and
    Franklin A; Yaxley WJ; Raveenthiran S; Coughlin G; Gianduzzo T; Kua B; McEwan L; Wong D; Delahunt B; Egevad L; Samaratunga H; Brown N; Parkinson R; Roberts MJ; Yaxley JW
    BJU Int; 2021 Jan; 127(1):71-79. PubMed ID: 32524748
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Kopp J; Kopp D; Bernhardt E; Manka L; Beck A; Gerullis H; Karakiewicz P; Schoerner W; Hammerer P; Schiffmann J
    World J Urol; 2020 Dec; 38(12):3085-3090. PubMed ID: 32103332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 68Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography-Based Primary Staging and Histological Correlation after Extended Pelvic Lymph Node Dissection in Intermediate-Risk Prostate Cancer.
    Kopp D; Kopp J; Bernhardt E; Manka L; Beck A; Gerullis H; Karakiewicz PI; Salomon G; Wiggermann P; Hammerer P; Schiffmann J
    Urol Int; 2022; 106(1):56-62. PubMed ID: 33965965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PSMA PET Scan Era: A Changing Paradigm PSMA PET and Lymph Node Dissection for Prostate Cancer Management.
    Haxhimolla J; Kua B; Gilbourd D; Haxhimolla H
    Semin Oncol Nurs; 2020 Aug; 36(4):151044. PubMed ID: 32723519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients.
    Beheshti M; Imamovic L; Broinger G; Vali R; Waldenberger P; Stoiber F; Nader M; Gruy B; Janetschek G; Langsteger W
    Radiology; 2010 Mar; 254(3):925-33. PubMed ID: 20177103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the accuracy of [
    Ingvar J; Hvittfeldt E; Trägårdh E; Simoulis A; Bjartell A
    EJNMMI Res; 2022 Aug; 12(1):48. PubMed ID: 35943665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of [18F]fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection.
    Häcker A; Jeschke S; Leeb K; Prammer K; Ziegerhofer J; Sega W; Langsteger W; Janetschek G
    J Urol; 2006 Nov; 176(5):2014-8; discussion 2018-9. PubMed ID: 17070241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ¹⁸F-fluorocholine PET/CT compared with extended pelvic lymph node dissection in high-risk prostate cancer.
    Kjölhede H; Ahlgren G; Almquist H; Liedberg F; Lyttkens K; Ohlsson T; Bratt O
    World J Urol; 2014 Aug; 32(4):965-70. PubMed ID: 24141889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The diagnostic accuracy of
    Rajwa P; Heidenreich J; Drzezga A; Schmidt M; Shariat SF; Heidenreich A
    Prostate; 2024 Jan; 84(1):74-78. PubMed ID: 37750292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary lymph-node staging with
    Corona-Montes VE; González-Cuenca E; Fernández-Noyola G; Olarte-Casas MA; Bobadilla-Salazar D; Medrano-Urtecho HM; Asimakopoulos AD
    Urol Oncol; 2021 Aug; 39(8):494.e1-494.e6. PubMed ID: 33223371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of lymph node metastases in patients with prostate cancer: Comparing conventional and digital [
    Bjöersdorff M; Puterman C; Oddstig J; Amidi J; Zackrisson S; Kjölhede H; Bjartell A; Wollmer P; Trägårdh E
    Clin Physiol Funct Imaging; 2022 Nov; 42(6):381-388. PubMed ID: 35866190
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Esen T; Falay O; Tarim K; Armutlu A; Koseoglu E; Kilic M; Seymen H; Sarikaya AF; Kiremit MC; Balbay MD; Canda AE; Baydar DE; Kordan Y; Demirkol MO; Tilki D
    Eur Urol Focus; 2021 Mar; 7(2):288-293. PubMed ID: 33509671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modelling Study with an Interactive Model Assessing the Cost-effectiveness of
    Scholte M; Barentsz JO; Sedelaar JPM; Gotthardt M; Grutters JPC; Rovers MM
    Eur Urol Focus; 2020 Sep; 6(5):967-974. PubMed ID: 30826284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymph node staging with fluorine-18 prostate specific membrane antigen 1007-positron emission tomography/computed tomography in newly diagnosed intermediate- to high-risk prostate cancer using histopathological evaluation of extended pelvic node dissection as reference.
    Hermsen R; Wedick EBC; Vinken MJM; van Kalmthout LWM; Küsters-Vandevelde HVN; Wijers CHW; Somford DM; van Basten JA
    Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3929-3937. PubMed ID: 35543733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distribution of prostate cancer recurrences on gallium-68 prostate-specific membrane antigen (
    Huits TH; Luiting HB; van der Poel HG; Nandurkar R; Donswijk M; Schaake E; Vogel W; Roobol MJ; Wit E; Stricker P; Emmett L; van Leeuwen PJ
    BJU Int; 2020 Jun; 125(6):876-883. PubMed ID: 32181951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.